Lyell Immunopharma (NASDAQ:LYEL) Shares Up 4.2% – Here’s What Happened

by · The Cerbat Gem

Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Free Report)’s share price traded up 4.2% during trading on Monday . The company traded as high as $35.98 and last traded at $36.5650. 51,379 shares were traded during mid-day trading, a decline of 30% from the average session volume of 73,281 shares. The stock had previously closed at $35.09.

Wall Street Analyst Weigh In

A number of analysts have weighed in on LYEL shares. HC Wainwright raised shares of Lyell Immunopharma from a “neutral” rating to a “buy” rating and increased their target price for the company from $20.00 to $45.00 in a research report on Tuesday, December 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Lyell Immunopharma currently has an average rating of “Hold” and an average price target of $45.00.

Read Our Latest Analysis on LYEL

Lyell Immunopharma Trading Down 2.1%

The firm’s 50-day moving average price is $24.13 and its 200 day moving average price is $16.33. The company has a market cap of $657.08 million, a price-to-earnings ratio of -1.32 and a beta of -0.11.

Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) last released its earnings results on Wednesday, November 12th. The company reported ($2.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.81) by $0.68. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.01 million. Lyell Immunopharma had a negative net margin of 794,292.69% and a negative return on equity of 96.68%. Analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Institutional Trading of Lyell Immunopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. ARCH Venture Management LLC raised its stake in Lyell Immunopharma by 51.5% during the 3rd quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company’s stock worth $44,807,000 after buying an additional 938,438 shares during the period. Almitas Capital LLC increased its holdings in shares of Lyell Immunopharma by 136.3% during the first quarter. Almitas Capital LLC now owns 2,482,606 shares of the company’s stock valued at $1,336,000 after acquiring an additional 1,432,086 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Lyell Immunopharma by 76.0% during the third quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock worth $12,651,000 after purchasing an additional 336,378 shares during the period. Acadian Asset Management LLC raised its position in shares of Lyell Immunopharma by 204.2% during the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock worth $354,000 after purchasing an additional 443,614 shares during the period. Finally, Nuveen LLC bought a new position in shares of Lyell Immunopharma in the 1st quarter worth $345,000. 66.05% of the stock is owned by institutional investors.

Lyell Immunopharma Company Profile

(Get Free Report)

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.

Featured Stories